|
|
- 2018
苯甲酰新乌头原碱对骨髓瘤细胞RPMI8226增殖及凋亡的影响
|
Abstract:
摘要 目的:探究苯甲酰新乌头原碱(BMA)对骨髓瘤细胞RPMI8226(RPMI8226)增殖及凋亡的影响.方法:将对数期生长RPMI8226细胞随机分为空白对照组、BMA(0.1、0.5、1、10、100 μmoL) 组,24 h后用CCK8测定各组光密度(A),根据A值计算出半数抑制质量浓度(IC50);根据所测IC50将对数期生长RPMI8226细胞分为空白对照组、阴性对照组、BMA(4、6、8 μmoL)各组,作用12~48 h,用CCK8测定不同作用时间下各组RPMI8226细胞A值,计算出各组增殖抑制率;根据BMA对RMPI8226增殖抑制率的影响规律再设空白对照组、BMA(4、8 μmoL)组,作用24、48 h,用AnnexinV/PI双染色流式细胞术检测各组细胞凋亡率.结果:作用24 h后,各组BMA换算成质量浓度,在13~13 000 ng/mL(即1~10 μmoL)质量浓度,各组A值随药物质量浓度的增加而减少,P<0.05,其IC50质量浓度为1 040 ng/mL;作用12~48 h,各组细胞增殖抑制率随加入的BMA的增加、作用时间的增加而增加,各组P<0.05;作用24、48 h后各组细胞凋亡率随加入BMA的增加、作用的增加而增大,各组P<0.05.结论:BMA能抑制RPMI8226增殖并使其凋亡.
| [1] | NATIONAl COMPREHENSIVE CANCER NETWORK. Clinical practice guide-lines in oncology: multiple myeloma. (Version 3) [R/OL]. [2018-12-17].http://www.nccn.org/professionals/physiciangls/pdf/myeloma.pdf. |
| [2] | UNITED STATES FOOD AND DRUG ADMINISTRATION. Ninlaro: statistical review and evaluation[R/OL].[2017-02-13].https://www.fda.gov/Drugs/InformationOnDrugs/ucm482023.htm. |
| [3] | 李诗雅. 65例多发性骨髓瘤患者免疫表型特点及预后因素分析[D].太原:山西医科大学,2016. |
| [4] | MEI H L.Studies on the detoxification and pharmacological effects of different processing methods on the processing of aconitum diphtheria[D]. Wulumuqi:Xinjiang Medical University, 2014. |
| [5] | 方莉. 不同炮制模型对附子化学成分的影响及其指纹图谱的研究[D].广州:广州中医药大学,2013. |
| [6] | FANG L.Studies on the effects of different processing models on the Chemical constituents of Aconitum chinensis and their fingerprints[D]. Guangzhou:Guangzhou University of traditional Chinese Medicine, 2013. |
| [7] | 张霞,陈迎平.HPLC同时测定人血浆中新乌头碱、乌头碱、次乌头碱和苯甲酰新乌头原碱的含量[J].中药材,2014,37(8):1407-1409. |
| [8] | WANG Z J.Studies on the Mechanism and function of HSP90 inhibitor targeting NOTCH1 in T-ALL and the Mechanism of MWCNTs inhibiting Pgp and MRP4[D]. Wuhan:Huazhong University of Science and Technology, 2016. |
| [9] | 倪海雯,姜鹏君,孔祥图.补肾解毒化瘀方联合CPT化疗方案治疗老年多发性骨髓瘤临床观察[J].安徽中医药大学学报,2016,35(6):27-32. |
| [10] | NI H W, JIANG P J, KONG X T.Clinical observation of Bushen jiedu Huayu recipe combined with CPT chemotherapy in the treatment of senile multiple Myeloma[J]. Journal of Anhui University of traditional Chinese Medicine, 2016,35(6): 27-32. |
| [11] | 黄智莉,陈志雄,于天启,等.多发性骨髓瘤中医证型聚类分析研究[J].新中医,2011,43(10):78-80. |
| [12] | HUANG Z L, CHEN Z H, YU T Q, et al.Cluster analysis of syndrome types of multiple myeloma in TCM[J]. New Chinese Medicine, 2011,43(10): 78-80. |
| [13] | 王琦侠. 多发性骨髓瘤病因不良预后和生活质量的影响因素研究[D].西安:第四军医大学,2012. |
| [14] | WANG Q X.Study on the influencing factors of poor prognosis and quality of life in multiple myeloma[D]. Xi'an:Fourth military Medical University, 2012. |
| [15] | BIRD J M, OWEN R G, D’SA S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011[J]. Br J Haematol, 2011,154(1):32-75. |
| [16] | 武贤达,孙丽霞,吕鸿雁,等.多发性骨髓瘤治疗新进展[J].临床荟萃,2017,32(7):627-632. |
| [17] | WU X D, SUN L X, LU H Y, et al.Progress in the treatment of multiple myeloma[J]. Clinical meta, 2017,2(7): 627-632. |
| [18] | LI S Y.Analysis of immunophenotype and prognostic factors in 65 patients with multiple myeloma[D]. Taiyuan:Shanxi Medical University, 2016. |
| [19] | ENGELHARDT M, TERPOS E, KLEBER M, et al.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma[J]. Haematologica, 2014,99(2):232-242. |
| [20] | 刘波, 白庆咸, 陈协群, 等.姜黄素对人多发性骨髓瘤细胞表达Survivin、Bcl-2、Bax的影响[J].中国实验血液学杂志, 2007,15(4):762-766. |
| [21] | LIU B, BAI Q X, CHEN X Q, et al.Effect of curcumin on expression of Survivin,Bcl-2,Bax in human multiple myeloma cells[J]. Chinese Journal of Experimental Hematology, 2007,15(4): 762-766. |
| [22] | 杨军军, 高申孟, 陈慧,等.苦参碱诱导多发性骨髓瘤细胞株RPMI8226凋亡的实验研究[J].中国实验血液学杂志, 2007,15(3):625-634. |
| [23] | YANG J J, GAO S M, CHEN H, et al.Experimental study of Matrine induced apoptosis in multiple myeloma cell line RPMI8226[J]. Chinese Journal of Experimental Hematology, 2007,15(3): 625-634. |
| [24] | 傅爱林,沈文香,罗青松.三氧化二砷联合沙利度胺加地塞米松治疗难治性、复发性多发性骨髓瘤19例疗效分析[J].湖南中医药大学学报,2010,30(10):50-51+56. |
| [25] | FU A L, SHEN W X, LUO Q S.Analysis of curative effect of arsenic trioxide combined with thalidomide plus dexamethasone in the treatment of 19 cases of refractory and recurrent multiple myeloma[J]. Journal of Hunan University of traditional Chinese Medicine, 2010,30(10): 50-51,56. |
| [26] | 练诗梅,王晓波,薛祖光,等.亚砷酸联合化疗治疗复发/难治性多发性骨髓瘤[J].实用肿瘤杂志,2007(2):170-172. |
| [27] | LIN S M, WANG X B, XUE Z G, et al.Combined arsenite chemotherapy for recurrent / refractory multiple myeloma[J]. Journal of practical Cancer, 2007(2): 170-172. |
| [28] | 关心,杨同华,张爱玲,等.附子中的新乌头碱对K562细胞增殖和凋亡的影响[J].北京中医药大学学报,2015,38(7):467-472+2. |
| [29] | GUAN X, YANG T H, ZHANG A L, et al.Effects of aconitine in aconitine on proliferation and apoptosis of K562 cells[J]. Journal of Beijing University of traditional Chinese Medicine, 2015(7): 467-472. |
| [30] | 梅海霖. 不同炮制方法对白喉乌头炮制减毒及药理作用研究[D].乌鲁木齐:新疆医科大学,2014. |
| [31] | ZHANG X, CHEN Y P.Simultaneous determination of new aconitine, hypoaconitine and benzoyl new aconitine in human plasma by HPLC[J]. Chinese herbal medicine, 2014, 37(8): 1407-1409. |
| [32] | 王召静. HSP90抑制剂在T-ALL中靶向NOTCH1的机制和功能研究及MWCNTs抑制Pgp和MRP4的机制研究[D].武汉:华中科技大学,2016. |
| [33] | MOREAU P, SAN MIGUEL J, SONNEVELD P, et al. Multiple myeloma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(S4):iv52-iv61. |
